145 related articles for article (PubMed ID: 20840107)
21. Vector delivery technique affects gene transfer in the cornea in vivo.
Mohan RR; Sharma A; Cebulko TC; Tandon A
Mol Vis; 2010 Nov; 16():2494-501. PubMed ID: 21139995
[TBL] [Abstract][Full Text] [Related]
22. A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System.
Guggino WB; Benson J; Seagrave J; Yan Z; Engelhardt J; Gao G; Conlon TJ; Cebotaru L
Hum Gene Ther Clin Dev; 2017 Sep; 28(3):145-156. PubMed ID: 28726496
[TBL] [Abstract][Full Text] [Related]
23. Efficient Transduction of Corneal Stroma by Adeno-Associated Viral Serotype Vectors for Implications in Gene Therapy of Corneal Diseases.
Lu Y; Ai J; Gessler D; Su Q; Tran K; Zheng Q; Xu X; Gao G
Hum Gene Ther; 2016 Aug; 27(8):598-608. PubMed ID: 27001051
[TBL] [Abstract][Full Text] [Related]
24. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size.
Yang GS; Schmidt M; Yan Z; Lindbloom JD; Harding TC; Donahue BA; Engelhardt JF; Kotin R; Davidson BL
J Virol; 2002 Aug; 76(15):7651-60. PubMed ID: 12097579
[TBL] [Abstract][Full Text] [Related]
25. Astrocyte-selective AAV gene therapy through the endogenous GFAP promoter results in robust transduction in the rat spinal cord following injury.
Griffin JM; Fackelmeier B; Fong DM; Mouravlev A; Young D; O'Carroll SJ
Gene Ther; 2019 May; 26(5):198-210. PubMed ID: 30962538
[TBL] [Abstract][Full Text] [Related]
26. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.
Xin KQ; Mizukami H; Urabe M; Toda Y; Shinoda K; Yoshida A; Oomura K; Kojima Y; Ichino M; Klinman D; Ozawa K; Okuda K
J Virol; 2006 Dec; 80(24):11899-910. PubMed ID: 17005662
[TBL] [Abstract][Full Text] [Related]
27. AAV5-mediated gene transfer to the parotid glands of non-human primates.
Voutetakis A; Zheng C; Cotrim AP; Mineshiba F; Afione S; Roescher N; Swaim WD; Metzger M; Eckhaus MA; Donahue RE; Dunbar CE; Chiorini JA; Baum BJ
Gene Ther; 2010 Jan; 17(1):50-60. PubMed ID: 19759566
[TBL] [Abstract][Full Text] [Related]
28. Vector serotype screening for use in ovine perinatal lung gene therapy.
McClain LE; Davey MG; Zoltick PW; Limberis MP; Flake AW; Peranteau WH
J Pediatr Surg; 2016 Jun; 51(6):879-84. PubMed ID: 27032612
[TBL] [Abstract][Full Text] [Related]
29. Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons.
Mason MR; Ehlert EM; Eggers R; Pool CW; Hermening S; Huseinovic A; Timmermans E; Blits B; Verhaagen J
Mol Ther; 2010 Apr; 18(4):715-24. PubMed ID: 20179682
[TBL] [Abstract][Full Text] [Related]
30. AAV Gene Therapy for MPS1-associated Corneal Blindness.
Vance M; Llanga T; Bennett W; Woodard K; Murlidharan G; Chungfat N; Asokan A; Gilger B; Kurtzberg J; Samulski RJ; Hirsch ML
Sci Rep; 2016 Feb; 6():22131. PubMed ID: 26899286
[TBL] [Abstract][Full Text] [Related]
31. A combined therapeutic approach for pyruvate dehydrogenase deficiency using self-complementary adeno-associated virus serotype-specific vectors and dichloroacetate.
Han Z; Berendzen K; Zhong L; Surolia I; Chouthai N; Zhao W; Maina N; Srivastava A; Stacpoole PW
Mol Genet Metab; 2008 Apr; 93(4):381-7. PubMed ID: 18206410
[TBL] [Abstract][Full Text] [Related]
32. Caspase inhibition with XIAP as an adjunct to AAV vector gene-replacement therapy: improving efficacy and prolonging the treatment window.
Yao J; Jia L; Khan N; Zheng QD; Moncrief A; Hauswirth WW; Thompson DA; Zacks DN
PLoS One; 2012; 7(5):e37197. PubMed ID: 22615940
[TBL] [Abstract][Full Text] [Related]
33. MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain.
Samaranch L; Blits B; San Sebastian W; Hadaczek P; Bringas J; Sudhakar V; Macayan M; Pivirotto PJ; Petry H; Bankiewicz KS
Gene Ther; 2017 Apr; 24(4):253-261. PubMed ID: 28300083
[TBL] [Abstract][Full Text] [Related]
34. OneBac 2.0: Sf9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA.
Mietzsch M; Casteleyn V; Weger S; Zolotukhin S; Heilbronn R
Hum Gene Ther; 2015 Oct; 26(10):688-97. PubMed ID: 26134901
[TBL] [Abstract][Full Text] [Related]
35. Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates.
Fischer AC; Smith CI; Cebotaru L; Zhang X; Askin FB; Wright J; Guggino SE; Adams RJ; Flotte T; Guggino WB
Mol Ther; 2007 Apr; 15(4):756-63. PubMed ID: 17299412
[TBL] [Abstract][Full Text] [Related]
36. Preparation and Administration of Adeno-associated Virus Vectors for Corneal Gene Delivery.
Song L; Bower JJ; Hirsch ML
Methods Mol Biol; 2020; 2145():77-102. PubMed ID: 32542602
[TBL] [Abstract][Full Text] [Related]
37. New strategy for in vivo transgene expression in corneal epithelial progenitor cells.
Igarashi T; Miyake K; Suzuki N; Kato K; Takahashi H; Ohara K; Shimada T
Curr Eye Res; 2002 Jan; 24(1):46-50. PubMed ID: 12187494
[TBL] [Abstract][Full Text] [Related]
38. The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5.
Weinberg MS; Blake BL; Samulski RJ; McCown TJ
Gene Ther; 2011 Oct; 18(10):961-8. PubMed ID: 21490684
[TBL] [Abstract][Full Text] [Related]
39. Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina.
Lotery AJ; Yang GS; Mullins RF; Russell SR; Schmidt M; Stone EM; Lindbloom JD; Chiorini JA; Kotin RM; Davidson BL
Hum Gene Ther; 2003 Nov; 14(17):1663-71. PubMed ID: 14633408
[TBL] [Abstract][Full Text] [Related]
40. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
Janelidze S; Nordström U; Kügler S; Brundin P
J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
